Nanobiotix Aktie [WKN DE: A1J7EB / ISIN: FR0011341205]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Nanobiotix SA

20.07.23		Voting Rights and Shares Capital of the Company (GlobeNewswire)
19.07.23		NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers (GlobeNewswire)
10.07.23		NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3 (GlobeNewswire)
08.06.23		Voting Rights and Shares Capital of the Company (GlobeNewswire)
17.05.23		NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update (GlobeNewswire)
05.05.23		NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company (GlobeNewswire)
25.04.23		NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
17.04.23		NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023 (GlobeNewswire)
11.04.23		Voting Rights and Shares Capital of the Company (GlobeNewswire)
27.03.23		Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call (GlobeNewswire)
14.03.23		Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023 (GlobeNewswire)
14.02.23		Voting Rights and Shares Capital of the Company (GlobeNewswire)
10.10.22		Nanobiotix: Voting Rights and Shares Capital of the Company (Businesswire)
28.09.22		Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022 (Businesswire)
22.09.22		Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022 (Businesswire)
21.09.22		Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy (Businesswire)
12.09.22		Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024 (Businesswire)
08.09.22		Nanobiotix: Voting Rights and Shares Capital of the Company (Businesswire)
07.09.22		NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer (Businesswire)
06.09.22		NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences (Businesswire)
31.08.22		Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022 (Businesswire)
09.08.22		NANOBIOTIX: Voting Rights and Shares Capital of the Company (Businesswire)
13.07.22		Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont (Businesswire)
08.07.22		Nanobiotix: Voting Rights and Shares Capital of the Company (Businesswire)
09.06.22		NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
05.06.22		NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications (Businesswire)
02.06.22		NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 (Businesswire)
19.05.22		CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update (Businesswire)
18.05.22		NANOBIOTIX Provides First Quarter Operational and Financial Update (Businesswire)
17.05.22		NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022 (Businesswire)
11.05.22		NANOBIOTIX to Participate in Two Upcoming Investor Conferences (Businesswire)
10.05.22		Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
04.05.22		NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022 (Businesswire)
02.05.22		New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting (Businesswire)
11.04.22		NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3 (Businesswire)
08.04.22		NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F (Businesswire)
07.04.22		Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
30.03.22		NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results (Businesswire)
16.03.22		NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022 (Businesswire)
08.03.22		Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
10.02.22		Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
09.02.22		Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer (Businesswire)
26.01.22		NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 (Businesswire)
11.01.22		Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
10.01.22		NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets (Businesswire)
05.01.22		NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer (Businesswire)
04.01.22		Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022 (Businesswire)
08.12.21		Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
30.06.21		NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer (Businesswire)
01.06.21		NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Ripple explodiert – Jetzt investieren und Millionär werden?

Diese Aktien befinden sich Q3 2024 im Portfolio von Warren Buffett

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

thyssenkrupp-Aktie zieht dennoch an: thyssenkrupp mit weiterem Milliardenverlust

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 04:30
Kaufwert:	EUR
	Hinzufügen Speichern